The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Successful completion of business sale

2 May 2017 07:00

RNS Number : 7901D
Premier Veterinary Group PLC
02 May 2017
 

PREMIER VETERINARY GROUP PLC

 

("PVG", the "Company" or the "Group")

 

Successful completion of business sale

 

London, UK, 02 May 2017 - Premier Veterinary Group plc (LSE: PVG) announces today that, further to the announcement made on 3 March 2017, it has completed the sale of the business, trade and assets of its buying group ("the Premier Buying Group") to Animal Healthcare Services Limited, a subsidiary of Henry Schein, Inc. (the "Acquirer") for a cash consideration of £6.3million.

 

The Premier Buying Group offers enhanced discounts to member practices on pharmaceutical and consumable spending. All related employees will be transferred to the Acquirer. The Board believes that the Acquirer is well positioned to enhance the offer currently available to Premier Buying Group members.

 

The net cash proceeds after transaction costs and taxation of between £4.5m and £5.0m will, as previously announced, be used to repay all existing debt of £1.25m and further fund PVG's international growth plans for its Premier Pet Care Plan ("PPCP") business in both the USA and Europe.

 

For the year ended 30 September 2016, the Premier Buying Group contributed revenues and operating profit of £1,120k and £766k respectively. As at 30 September 2016, the book value of gross assets that are subject to the disposal were £100k. The disposal of the Premier Buying Group is expected to be earnings dilutive.

 

For further information, please contact:

 

 

Premier Veterinary Group plc

Tel: +44 (0)117 970 4130

Dominic Tonner, Chief Executive Officer

 

Will Evans, Chief Financial Officer 

 

 

 

Note to Editors:

 

PVG's services to third party veterinary practices, through its wholly-owned subsidiary, Premier Vet Alliance Limited ("PVA"), include the administration and support of a preventative healthcare programme for pets branded "Premier Pet Care Plan" ("PPCP"). In the US, where veterinary practices are known as veterinary hospitals, PPCP is marketed through the Company's wholly-owned subsidiary, Premier Vet Alliance (US) Limited.

 

PPCP is a structured, preventative healthcare programme for cats, dogs and rabbits and is available only through veterinary practices/hospitals. The programme is seen as a way of providing gold standard care for pets at an affordable price for the client, by way of fixed monthly payments.

 

PPCP uses a clinical approach to prevention, as this is the most effective method of ensuring illnesses are diagnosed more quickly and not given a chance to advance. What truly sets PPCP apart is its unique approach of offering an end-to-end solution and support to the practice/hospital, which has been proven to work extremely well. PVA works alongside practices/hospitals to create a tailor-made, cost-effective service for clients, one that delivers excellent care to their patients and significantly improves practice/hospital performance.

 

For further details:

http://www.premiervetalliance.co.uk/  

 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward- looking statements contained in this announcement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors readers are cautioned not to rely on any forward-looking statement.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISGCGDSBXXBGRG
Date   Source Headline
14th Jun 201011:45 amRNSForm 8.5 (EPT/RI)
14th Jun 20109:16 amRNSForm 8.5 (EPT/NON-RI)
11th Jun 20102:06 pmRNSForm 8.3 - Ark Therapeutics Group PLC
11th Jun 201012:46 pmRNSForm 8.3 - Ark Therapeutics Plc
11th Jun 201010:16 amRNSForm 8.5 (EPT/RI)
11th Jun 20109:52 amRNSForm 8.5 (EPT/NON-RI)
10th Jun 201010:17 amRNSForm 8.5 (EPT/NON-RI)
10th Jun 201010:13 amRNSForm 8.5 (EPT/RI)
9th Jun 201011:38 amRNSForm 8.5 (EPT/RI)
9th Jun 201010:08 amRNSForm 8.5 (EPT/NON-RI)
8th Jun 20104:40 pmRNSSecond Price Monitoring Extn
8th Jun 20104:35 pmRNSPrice Monitoring Extension
8th Jun 201012:36 pmRNSForm 8.3 - Ark Therapeutics
8th Jun 201011:15 amRNSForm 8.5 (EPT/NON-RI)
8th Jun 201011:11 amRNSForm 8.5 (EPT/RI)
7th Jun 20102:53 pmRNSForm 8.3 - Ark Therapeutics Group PLC
7th Jun 201011:55 amRNSForm 8.3 - [Ark Therapeutics Group plc]
7th Jun 201011:04 amRNSForm 8.5 (EPT/RI)-Amendment
7th Jun 201011:04 amRNSForm 8.5 (EPT/RI)
7th Jun 20109:41 amRNSForm 8.5 (EPT/NON-RI)
4th Jun 201012:43 pmRNSForm 8.3 - ARK THERAPEUTICS
4th Jun 201011:43 amRNSForm 8.5 (EPT/RI)
4th Jun 201010:25 amRNSForm 8.5 (EPT/NON-RI)
3rd Jun 20102:53 pmRNSForm 8.3 - Ark Therapeutics Group PLC
3rd Jun 201011:37 amRNSForm 8.5 (EPT/RI)
3rd Jun 201011:25 amRNSForm 8.5 (EPT/NON-RI)
3rd Jun 201010:28 amRNSBlocklisting Interim Review
2nd Jun 20103:07 pmRNSForm 8.3 - Ark Therapeutics Group PLC
2nd Jun 201011:38 amRNSForm 8.5 (EPT/RI)
2nd Jun 20109:22 amRNSForm 8.5 (EPT/NON-RI)
1st Jun 20102:47 pmRNSForm 8.3 - Ark Therapeutics Group PLC
1st Jun 20102:45 pmRNSForm 8.3 - Ark Therapeutics
1st Jun 201010:08 amRNSForm 8.5 (EPT/NON-RI)
28th May 201011:08 amRNSForm 8.5 (EPT/NON-RI)
27th May 20103:17 pmRNSForm 8.3 - Ark Therapeutics Group PLC
27th May 201010:41 amRNSForm 8.5 (EPT/RI)
27th May 20109:04 amRNSForm 8.5 (EPT/NON-RI)
26th May 201011:45 amRNSForm 8.5 (EPT/NON-RI)
25th May 20104:40 pmRNSSecond Price Monitoring Extn
25th May 20104:35 pmRNSPrice Monitoring Extension
25th May 201010:44 amRNSForm 8.5 (EPT/NON-RI)
24th May 20109:10 amRNSForm 8.5 (EPT/NON-RI)
24th May 20107:00 amRNSAppointment of CFO and Company Secretary
21st May 20103:32 pmRNSForm 8.5 (EPT/RI)
21st May 20109:55 amRNSForm 8.5 (EPT/NON-RI)
20th May 20109:50 amRNSForm 8.5 (EPT/NON-RI)
19th May 201010:48 amRNSForm 8.5 (EPT/NON-RI)
18th May 201011:05 amRNSForm 8.5 (EPT/NON-RI)
18th May 201010:11 amRNSForm 8.5 (EPT/RI)
18th May 20107:00 amRNSInterim Management Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.